Hubei Jumpcan Pharmaceutical Co., Ltd.
600566
Rang in Aktien
#4335
Hubei Jumpcan Pharmaceutical Co., Ltd. is a Chinese enterprise dedicated to the... Hubei Jumpcan Pharmaceutical Co., Ltd. is a Chinese enterprise dedicated to the full spectrum of pharmaceutical operations, encompassing research, development, production, and marketing. The company's product lines include both traditional Chinese and Western medicines, as well as daily-use chemical products incorporating traditional Chinese medicine, and health supplements rooted in Chinese medical practices. Their diverse range of Chinese and Western pharmaceuticals addresses a wide array of therapeutic areas, such as pediatric care, women's health, respiratory conditions, digestive disorders, and geriatric medicine. Additionally, their development pipeline covers treatments for detoxification, nervous system ailments, anti-infective agents, cardiovascular issues, pain relief, nutritional deficiencies, musculoskeletal problems, and blood clotting management. Beyond medicinal products, Jumpcan also manufactures oral and skin care items. The company's Chinese medicine-based health products are designed to provide benefits like fatigue reduction, anti-aging effects, antioxidant support, and immune system boosting. Headquartered in Taixing, China, the company adopted its current name, Hubei Jumpcan Pharmaceutical Co., Ltd., in March 2015, having previously operated as Hubei Hongcheng General Machinery Co., Ltd.
Aktienkurs
$3.87
Marktkapitalisierung
$3.57B
Veränderung (1 Tag)
-1.64%
Veränderung (1 Jahr)
9.08%
Land
CN
Handel Hubei Jumpcan Pharmaceutical Co., Ltd. (600566)
Kategorie
Healthcare
P/S-Verhältnis für Hubei Jumpcan Pharmaceutical Co., Ltd. (600566)
P/S-Verhältnis zum October 2026 TTM: 4.11
Laut den neuesten Finanzberichten und dem Aktienkurs von Hubei Jumpcan Pharmaceutical Co., Ltd. beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 4.11. Am Ende des Jahres 2024 lag das P/S-Verhältnis bei 3.33.
P/S-Verlauf für Hubei Jumpcan Pharmaceutical Co., Ltd. von 2001 bis 2026
P/S-Verhältnis zum Jahresende
| Jahr | P/S-Verhältnis | ändert |
|---|---|---|
| 2026 (TTM) | 4.11 | 5.33% |
| 2025 | 3.90 | 17.09% |
| 2024 | 3.33 | 5.25% |
| 2023 | 3.16 | 17.43% |
| 2022 | 2.69 | -18.41% |
| 2021 | 3.30 | 20.44% |
| 2020 | 2.74 | -3.52% |
| 2019 | 2.84 | -16.43% |
| 2018 | 3.40 | -38.21% |
| 2017 | 5.50 | 3.16% |
| 2016 | 5.33 | -6.66% |
| 2015 | 5.71 | 11.68% |
| 2014 | 5.11 | 2.56% |
| 2013 | 4.99 | 137.31% |
| 2012 | 2.10 | -42.77% |
| 2011 | 3.67 | -34.21% |
| 2010 | 5.58 | 46.57% |
| 2009 | 3.81 | 71.52% |
| 2008 | 2.22 | -53.32% |
| 2007 | 4.76 | 93.14% |
| 2006 | 2.46 | -7.59% |
| 2005 | 2.66 | -30.87% |
| 2004 | 3.85 | -40.48% |
| 2003 | 6.47 | -41.82% |
| 2002 | 11.13 | -26.20% |
| 2001 | 15.08 | 0.00% |
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | P/S-Verhältnis | P/S-Verhältnis-Differenz | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| 2.19 | -46.76% |
JP
|
|
| 8.92 | 117.17% |
CH
|
|
| 7.06 | 71.81% |
IN
|
